Shares of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Brokerages have set a 1 year consensus price objective of $10.00 for the company and are anticipating that the company will post ($0.69) EPS for the current quarter, according to Zacks. Zacks has also assigned Diffusion Pharmaceuticals an industry rank of 53 out of 256 based on the ratings given to related companies.
Several research analysts have issued reports on the company. ValuEngine cut Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. HC Wainwright reissued a “buy” rating on shares of Advanced Emissions Solutions in a research report on Wednesday, March 20th.
NASDAQ:DFFN remained flat at $$2.18 on Friday. The company’s stock had a trading volume of 230,606 shares, compared to its average volume of 116,902. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.35 and a quick ratio of 5.35. The business has a 50-day simple moving average of $2.97. Diffusion Pharmaceuticals has a fifty-two week low of $1.83 and a fifty-two week high of $11.00.
Diffusion Pharmaceuticals (NASDAQ:DFFN) last announced its earnings results on Thursday, May 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.09. As a group, equities analysts forecast that Diffusion Pharmaceuticals will post -2.27 earnings per share for the current year.
An institutional investor recently bought a new position in Diffusion Pharmaceuticals stock. Two Sigma Investments LP acquired a new position in shares of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 32,176 shares of the company’s stock, valued at approximately $64,000. Two Sigma Investments LP owned approximately 0.95% of Diffusion Pharmaceuticals as of its most recent SEC filing. 6.20% of the stock is currently owned by institutional investors.
Diffusion Pharmaceuticals Company Profile
Diffusion Pharmaceuticals Inc, a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke.
Read More: What is meant by a buy rating?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.